DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ppf28f/pertussis) has announced the addition of the "Pertussis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co., Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- Bharat Biotech International Limited
- Biological E. Limited
- Boryung Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
- DBV Technologies S.A.
- GlaxoSmithKline Plc
- Green Cross Corporation
- Immunovaccine, Inc.
- Indian Immunologicals Limited
- LG Life Sciences Limited
- NanoBio Corporation
- Panacea Biotec Limited
- Sanofi
- Sanofi Pasteur SA
- Serum Institute of India Limited
- Sinovac Biotech Ltd.
- Synthetic Biologics, Inc.
- Zydus Cadila Healthcare Limited
Drug Profiles
- (diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine
- (diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B]) vaccine
- (diphtheria + tetanus + pertussis (whole-cell)) vaccine
- (diphtheria + tetanus + pertussis) vaccine
- diphtheria + pertussis (acellular) + tetanus vaccine
- diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine
- diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine
- diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine
- diphtheria + tetanus + pertussis (acellular) vaccine
- diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine
- diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine
- diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine
- diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine
- diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine
- diphtheria + tetanus+ pertussis (whole cell) vaccine
- diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine
- diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine
- GC-3111A
- pertussis (acellular) vaccine
- pertussis (whole-cell) vaccine
- pertussis + hepatitis B vaccine
- pertussis vaccine
- PR-5I
- Recombinant BCG - Pertussis Vaccine
- SYN-005
- tetanus + diphtheria + pertussis (acellular) vaccine
- VN-0103
For more information visit http://www.researchandmarkets.com/research/ppf28f/pertussis
